Morgan Stanley Maintains LifeStance Health(LFST.US) With Buy Rating, Maintains Target Price $10
LifeStance Health Gr Analyst Ratings
UBS Maintains Neutral on LifeStance Health Gr, Lowers Price Target to $7.5
LifeStance Health Gr Analyst Ratings
Barclays Sticks to Their Sell Rating for Lifestance Health Group (LFST)
Robust Growth and Strong Financials Drive Buy Rating for Lifestance Health Group
Morgan Stanley Maintains LifeStance Health(LFST.US) With Buy Rating, Maintains Target Price $10
Buy Rating Affirmed for LifeStance Health Amid Recovery Prospects and Strategic Payor Engagements
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Lifestance Health Group (LFST) and Agilent (A)
Barclays Reaffirms Their Sell Rating on Lifestance Health Group (LFST)
LifeStance Health Gr Analyst Ratings
Morgan Stanley Reiterates Overweight on LifeStance Health Gr, Maintains $10 Price Target
Analysts Are Bullish on These Healthcare Stocks: Lifestance Health Group (LFST), LifeMD (LFMD)
LifeStance Health Gr Analyst Ratings
Jefferies Maintains Buy on LifeStance Health Gr, Raises Price Target to $9
LifeStance Health Gr Analyst Ratings
Lifestance Health Group Maintains Hold Rating With Limited Valuation Potential Despite Positive Trends
Barclays Adjusts LifeStance Health Group Price Target to $8 From $7, Maintains Underweight Rating
Lifestance Health Group: A Buy Rating With Promising Financial and Operational Upside
Barclays Keeps Their Sell Rating on Lifestance Health Group (LFST)
No Data
No Data